Homocysteine predicts adverse clinical outcomes in unstable angina and non-ST elevation myocardial infarction: implications from the folate intervention in non-ST elevation myocardial infarction and unstable angina study

Coronary Artery Disease
Jose B Nevado, Marcelo Severino B Imasa

Abstract

Unstable angina and non-ST elevation myocardial infarction (NSTEMI) are common acute coronary events. Homocysteine is a novel risk factor for coronary heart diseases. Together with the conventional risk factors, they may affect the outcome of non-ST coronary events. This study aims to determine the effect of clinical risk factors that are responsible for the occurrence of mortality, and the composite outcome of mortality, nonfatal myocardial infarction and serious rehospitalization within 6 months after the onset of non-ST acute coronary syndromes. A total of 124 Filipino patients were interviewed and tested for blood homocysteine levels and lipid profiles. Outcomes were assessed after 6 months. Homocysteinemia (>16 micromol/l) is associated with increased mortality and composite outcomes (mortality, nonfatal reinfarction, and serious rehospitalization), even if adjusted for conventional risk factors. No association was detected for the conventional risk factors. Earlier acute coronary syndrome was found to be positively associated with mortality and the composite outcomes. Early stroke is associated with increased composite outcomes, whereas greater mortality and adverse outcomes were observed in NSTEMI compared with intermedi...Continue Reading

References

Nov 15, 1995·JAMA : the Journal of the American Medical Association·O NygårdG Kvåle
Oct 4, 1995·JAMA : the Journal of the American Medical Association·C J BousheyA G Motulsky
Jul 24, 1997·The New England Journal of Medicine·O NygårdS E Vollset
Aug 2, 2000·The American Journal of Clinical Nutrition·P M UelandS E Vollset
Jul 27, 2001·Diabetes Care·J B MeigsUNKNOWN Framingham Offspring Study
Sep 10, 2002·Arquivos brasileiros de cardiologia·José Roberto TavaresAntonio C Carvalho
Oct 26, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN Homocysteine Studies Collaboration
Aug 21, 2003·JAMA : the Journal of the American Medical Association·Umesh N KhotEric J Topol
Jun 10, 2004·JAMA : the Journal of the American Medical Association·Kim A EagleUNKNOWN GRACE Investigators
Jun 25, 2004·The New England Journal of Medicine·Helmut LangeJan-Henk E Dambrink
Mar 15, 2006·The New England Journal of Medicine·Eva LonnUNKNOWN Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators
Mar 15, 2006·The New England Journal of Medicine·Kaare Harald BønaaUNKNOWN NORVIT Trial Investigators
Apr 14, 2006·Journal of Hypertension·Gian Paolo RossiAchille C Pessina
Apr 14, 2006·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·J R Faria-NetoP L da Luz
May 12, 2006·The American Journal of Geriatric Cardiology·Claudia F GravinaLeopoldo Piegas
Jun 10, 2006·Cardiology·Martijn G H van OijenFreek W A Verheugt
Jun 16, 2006·Atherosclerosis·J A TroughtonUNKNOWN PRIME Study Group
Dec 14, 2006·JAMA : the Journal of the American Medical Association·Lydia A BazzanoJiang He

❮ Previous
Next ❯

Citations

Aug 27, 2011·Antioxidants & Redox Signaling·Zhi-Gang SheDe-Pei Liu
Nov 26, 2008·European Heart Journal·Charalambos AntoniadesChristodoulos Stefanadis
May 30, 2009·Lipids in Health and Disease·Mohammad ShojaieGhafar Shafaie
Mar 31, 2015·BMJ Case Reports·Hazlyna KamaruddinJulian Gunn
Feb 15, 2011·Thrombosis Research·Derrick L SaulsMaureane Hoffman
May 6, 2014·Archivos de cardiología de México·José Angel González-PliegoDiego Armando Gudiño-Amezcua

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.